Results 61 to 70 of about 38,153 (235)

Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers

Respirology Case Reports, 2021
We report a case of anti‐transcriptional intermediary factor 1γ (TIF1γ) antibody‐positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high‐dose intravenous immunoglobulin (IVIg), and ...
Ryosuke Imai, Sumie Ikemura, Torahiko Jinta   +2 more
doaj   +1 more source

Improved Detection of Myositis‐Specific Autoantibodies Using Luciferase Immunoprecipitation Systems Assay: Comparison with Line Blot and Conventional Immunoprecipitation

Arthritis &Rheumatology, Accepted Article.
Background Myositis‐specific autoantibodies guide the diagnosis and classification of idiopathic inflammatory myopathies, but current immunoassays vary in accuracy, particularly for autoantibodies associated with interstitial lung disease. Objective To compare the performance of the luciferase immunoprecipitation systems (LIPS) assay with line blot and
Peter D. Burbelo, Iago Pinal‐Fernandez, Maria Casal‐Dominguez, Xin Tian, Shijinqiu Gao, Neha Gupta, Eric Robbins, John A. Chiorini, Christopher A. Mecoli, Lisa Christopher‐Stine, Livia Casciola‐Rosen, Andrew Mammen, Sonye K. Danoff, Anthony F. Suffredini, Julio A. Huapaya   +14 more
wiley   +1 more source

Interleukin‐2 deprived state of regulatory T cells and their recovery by low‐dose interleukin‐2 in patients with inflammatory myopathies

Arthritis &Rheumatology, Accepted Article.
Objective Regeneration and expansion of regulatory T cells (Treg) by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg‐IL‐2 axis emerge in ...
Justus Ohmes, Luisa R. Monne, Sara Comdühr, Fynn Gerlach, Hanna Grasshoff, Alexander Dübbers, Antje Müller, Alexander Scheffold, Gabriela Riemekasten, Reza Akbarzadeh, Jens Y. Humrich   +10 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

[Polymyositis-dermatomyositis recognized during the follow-up of a patient with type 2 diabetes]. [PDF]

, 2012
Polymyositis-dermatomyositis is a rare systemic autoimmune disease which belongs to the class of idiopathic inflammatory myopathies. The disease exhibits high inter-individual variability, but chronic myositis is a common feature.
Csóka, Mária, Dankó, Katalin, Samer F,   +2 more
core   +2 more sources

Biomaterial design strategies for enhancing mitochondrial transplantation therapy

BMEMat, EarlyView.
Biomaterials to facilitate mitochondrial transplantation therapy: biomaterials as barriers to protect mitochondria from pathophysiological microenvironments, like osmotic stress caused by the excessive concentration of calcium ion, reactive oxygen species, and advanced glycation end products; biomaterials integrating with biochemical cues to improve ...
Shaoyang Kang, Yushan Zhang, Hang Li, Sirui Peng, Donghao Lyu, Chunxiao Zhou, Sheng Ding, Zujian Feng, Pingsheng Huang, Chuangnian Zhang, Hongjun Wang, Deling Kong, Weiwei Wang   +12 more
wiley   +1 more source

Familial dermatomyositis [PDF]

Rheumatology, 1998
A case of familial dermatomyositis (DM) is reported in a 27-yr-old mother and her daughter aged 2 yr and 8 months. Familial DM is a rare occurrence and has never been reported in a child of < 4 yr old, although isolated cases of DM have been found in infants as young as 1 yr.
A, Andrews, P, Hickling, C, Hutton
openaire   +2 more sources

Limitations to the 6-Minute Walk Test in Dermatomyositis with Interstitial Lung Disease in comparison with Idiopathic Interstitial pneumonia

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2013
Although the relationship between muscle strength and exercise capacity has been demonstrated in dermatomyositis without lung dysfunction, little is known about the association between exercise capacity and interstitial lung disease in dermatomyositis ...
Fujiko Someya, Naoki Mugii
doaj   +1 more source

Case of a fatal lung disease in a child with juvenile dermatomyositis

Zdorovʹe Rebenka, 2017
The article presents a case of a fatal lung disease in a child with juvenile dermatomyositis. Juvenile dermatomyositis is a serious disease with an unpredictable course, and lung damage in juvenile dermatomyositis is one of the most severe manifestations
O.A. Oshlianska, L.I. Omelchenko, L.F. Slepova, O.P. Gladyshko, V.G. Ivanova, V.V. Krat   +5 more
doaj   +1 more source

Faecal Microbiota Transplantation in Anorexia Nervosa: A Systematic Review of Methodologies, Outcomes, and Challenges With Recommendations for Future Studies

European Eating Disorders Review, EarlyView.
ABSTRACT Objective Anorexia nervosa (AN) is a severe psychiatric disorder displaying an altered gut microbiome. Faecal microbiome transplantation (FMT) has emerged as a powerful research tool and potential treatment option in AN due to the microbiome‐gut‐brain axis. Current studies are limited and reveal variable FMT protocols.
Anna C. Thelen, Nele M. Korten, Larissa Blischke, Clara Voelz, Cordian Beyer, Jochen Seitz, Stefanie Trinh   +6 more
wiley   +1 more source